NCT06731140View on ClinicalTrials.gov

Reverse HER2-negative Immune Resistant Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
HER2 Negative Breast Cancer
Interventions
DRUG

Retinoic Acid

Retinoic acid 20mg tid, p.o.

DRUG

anti-PD-1 antibody and chemotherapy

PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER